Vanessa Ragaglia

Vanessa Ragaglia, PhD has worked in the field of biotechnology since 2000. Vanessa began their career as a Senior Scientist and Director of Preclinical Development at Garnet BioTherapeutics. In 2009, they were promoted to Vice President of Research Operations, where they established the company's strategic R&D roadmap and activities in support of portfolio strategy. In 2013, they moved to the role of Chief Scientific Officer at Garnet BioTherapeutics, where they served as a subject matter expert for cell therapeutics and defended and supported the IP portfolio. From 2014 to 2016, they were the Chief Scientific Officer at LZ Therapeutics, where they spearheaded the corporate research agenda to develop cell-based ganglioside pharmaceuticals for neurologic indications. Since 2016, they have been the Senior Director of Toxicology & Project Champion at Larimar Therapeutics Inc., where they report directly to the Chief Medical Officer and oversees all nonclinical safety assessment work for protein therapeutics to treat Orphan diseases.

Vanessa Ragaglia, PhD completed their Bachelor of Science in Biochemistry at Trinity College-Hartford. Vanessa then went on to pursue their PhD in Neuropharmacology at The Ohio State University College of Medicine, which they completed in 1996. Following this, they completed a Post Doctoral Fellowship in Neuropathology at the University of Pennsylvania. In November 2022, they will also receive their certification in DABT from the American Board of Toxicology, Inc.